2. Cell Cycle/DNA Damage Cytoskeleton Apoptosis Autophagy
  3. Microtubule/Tubulin Apoptosis Autophagy
  4. Nab-Paclitaxel

Nab-Paclitaxel  (Synonyms: Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007)

Cat. No.: HY-P99974 Purity: 99.70%
COA
SDS
Technical Support

Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11).

For research use only. We do not sell to patients.

Nab-Paclitaxel Chemical Structure

Nab-Paclitaxel Chemical Structure

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Nab-Paclitaxel Featured Recommendations:

Nab-Paclitaxel Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Nab-Paclitaxel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11)[1][2].

In Vitro

Nab-Paclitaxel (0.1 nM-10 μM, 72 h) is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line[3].
Nab-Paclitaxel (12-120 nM, 48 h) increases apoptotic RH4 cells and most cells detaches from the coveslips with higher concentration (60 or 120 nM)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Nab-Paclitaxel Related Antibodies

Cell Cytotoxicity Assay[3]

Cell Line: Three rhabdomyosarcoma cell lines(RH4, RH30, and RD), seven neuroblastoma cell lines (CHLA-20, CHLA-15, CHLA-90, LAN-5, SK-N-BE(2), BE(2)C, and SH-SY5Y) and one osteosarcoma cell line (KHOS)
Concentration: 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM
Incubation Time: 72 h
Result: Reduced the cell viability of the three rhabdomyosarcoma cell lines with IC50 ranging from 0.56 to 4.68 nM.
Exhibited dose-dependent cytotoxicity in seven neuroblastoma cell lines, where CHLA-20 has the highest IC50 of 36 nM.
In Vivo

Nab-Paclitaxel (30-50 mg/kg, i.v., administer on day 1, 8, 15) significantly inhibits RH4 tumor growth with tumor regression after second dosage on day 8 in mice bearing rhabdomyosarcoma (RH4 and RD) xenografts[3].
Nab-Paclitaxel (2-10 mg/kg, i.v., daily) significantly inhibits tumor growth with 5 and 10 mg/kg in neuroblastoma (SK-N-BE (2) and CHLA-20) xenograft (s.c.) mice[3].
Nab-Paclitaxel (50 mg/kg, i.v., weekly) has the strongest antitumor activity and significantly prolongs animal survival[3].
Nab-Paclitaxel (10 mg/kg, i.v., 5 consecutive days or 50 mg/kg, i.v., weekly) displays lower plasma paclitaxel concentrations but higher intratumor paclitaxel concentrations in both rhabdomyosarcoma and neuroblastoma mice model[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NOD/SCID (nonobese diabetic/severe combined immunodeficient) mice 4- to 6-week old bearing rhabdomyosarcoma (RH4 and RD) xenografts[3]
Dosage: 30, 50 mg/kg
Administration: Intravenous injection (i.v.), administer on day 1, 8, 15 then 52, 59, 66
Result: Exhibited lower toxicity to mice compared with Paclitaxel.
Increased local relapse-free intervals.
Significantly inhibited tumor growth and led to tumor shrinkage.
Remained sensitivity in mice with relapse RH4 xenografts against Nab-Paclitaxel whilst the xenografts were drug resistant against Paclitaxel.
Led to complete regression after day 29, but a few had relapsed tumor after 37 to 42 days.
Animal Model: Female NOD/SCID (nonobese diabetic/severe combined immunodeficient) mice 4- to 6-week old bearing rhabdomyosarcoma or neuroblastoma xenografts[3]
Dosage: 10 mg/kg for 5 consecutive days or 50 mg/kg weekly
Administration: Intravenous injection (i.v.)
Result: Significantly increased apoptotic cell population in a dose-dependent manner.
Increased phospho-histone H3-positive cells in a dose-dependent manner.
Induced G2-M cell-cycle arrest.
Clinical Trial
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Appearance

Solid

Color

White to off-white

SMILES

[Nab-Paclitaxel]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.70%

SDS (418 KB)

COA (231 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Nab-Paclitaxel Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nab-PaclitaxelNanoparticle albumin-bound Paclitaxel Nanoparticle albumin-bound ABI-007Microtubule/TubulinApoptosisAutophagyAlbuminantitumorbreast cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Nab-Paclitaxel
Cat. No.:
HY-P99974
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (418 KB) Français - FR (418 KB) Deutsch - DE (418 KB) Norwegian - NO (418 KB) Español - ES (418 KB) Swedish - SV (418 KB) Italian - IT (418 KB) Portuguese - PT (418 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.